DFDA

Desmopressin (DDAVP)

Treatment for Hemophilia

Typical Dosage: 0.3 mcg/kg IV or SC, or 150-300 mcg nasally; Max 2-3 doses in 24 hours

Effectiveness
70%
Safety Score
72%
Clinical Trials
8
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
0.3 mcg/kg IV or SC, or 150-300 mcg nasally; Max 2-3 doses in 24 hours
Time to Effect
immediate to 1 hour
Treatment Duration
acute treatment
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$200
Side Effect Mgmt:$300
Total Annual:$2,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$10,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$2,666.67
Comparison vs Recombinant Factor VIII (for mild HA)
Cost Difference
$-300,000/year
Less expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
DOMINATESBetter + cheaper
Prescription Access Economics
Annual Societal Loss per Patient
$1,350
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$60/year
Travel + wait time
Insurance Admin Cost
$40/year
Prior auth, claims
Rx Price
$1,500/year
Potential OTC Price
$500/year
Estimated if OTC available
Early Treatment Benefit
+0.00 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
MODERATE
Missed Diagnosis Risk
LOW
Requires Monitoring
Yes
Needs lab work/checkups
Desmopressin (DDAVP) Outcomes

for Hemophilia

Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+75%
Common Side Effects
Facial flushing
+35%
Headache
+20%
Hyponatremia
+8%
Dizziness
+8%

Sources:

nih.gov
hemophilianewstoday.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
5 completed trials for Desmopressin (DDAVP) in Hemophilia

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

NCT02506023COMPLETEDPHASE1
View Study
2 participants
INTERVENTIONAL
Atlanta, United States +1 more
Started: Jul 1, 2015

Exercise Versus DDAVP in Patients With Mild Hemophilia A

NCT03379974COMPLETEDPHASE4
View Study
32 participants
INTERVENTIONAL
Indianapolis, United States +3 more
Started: Jul 31, 2018

Efficacy and Safety of IL-11 in DDAVP Unresponsive

NCT00994929COMPLETEDPHASE2
View Study
9 participants
INTERVENTIONAL
Pittsburgh, United States
Started: Jan 1, 2010

Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A

NCT06020456COMPLETED
View Study
361 participants
OBSERVATIONAL
Bordeaux, France +11 more
Started: Jan 1, 2022

Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.

NCT03054662COMPLETEDNA
View Study
142 participants
INTERVENTIONAL
Abidjan, Côte d’Ivoire
Started: Jan 16, 2017